Clinical Trials Logo

Capecitabine clinical trials

View clinical trials related to Capecitabine.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06405490 Recruiting - Advanced Cancer Clinical Trials

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

NCT ID: NCT06202014 Recruiting - Pancreatic Cancer Clinical Trials

Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of concurrent radiotherapy with envafolimab and capecitabine in locally advanced pancreatic cancer.Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.

NCT ID: NCT06169202 Recruiting - Capecitabine Clinical Trials

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

Start date: June 1, 2023
Phase:
Study type: Observational

This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer.

NCT ID: NCT05970302 Recruiting - Capecitabine Clinical Trials

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Start date: July 7, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy,in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.

NCT ID: NCT05535413 Recruiting - Brain Metastases Clinical Trials

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.

NCT ID: NCT05290194 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Start date: March 28, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma.

NCT ID: NCT05022030 Recruiting - Colo-rectal Cancer Clinical Trials

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

CAPCET
Start date: July 21, 2021
Phase: Phase 2
Study type: Interventional

This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS and BRAF genes.

NCT ID: NCT02012634 Recruiting - Breast Cancer Clinical Trials

Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer

MACRO
Start date: January 2013
Phase: Phase 3
Study type: Observational

A Multi-center, III Phase,Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer